Professors

Search results

• NYU Langone: Drug Relieves Persistent Daydreaming, Fatigue & Brain Sluggishness in Adults with ADHD

  Jeffrey H. Newcorn & Beth Krone

  29/06/21

  1 item of Media coverage

  Press/Media

• Controversial New Alzheimer's Drug is Costly

  Samuel Gandy

  17/06/21

  5 items of Media coverage

  Press/Media

• "We Find a Way": Mount Sinai Launches National Brand and Advertising Campaign

  Kenneth L. Davis

  14/06/21 → 15/06/21

  6 items of Media coverage

  Press/Media

• "We Find a Way": Mount Sinai Launches National Brand and..

  Kenneth L. Davis

  14/06/21

  3 items of Media coverage

  Press/Media

• Newly Approved Antipsychotic for Schizophrenia and Bipolar I Disorder Lessens Weight Gain, Studies Show

  Rene Kahn

  4/06/21

  1 item of Media coverage

  Press/Media

• FDA Approves Lybalvi

  Rene Kahn

  2/06/21

  1 item of Media coverage

  Press/Media

• FDA green light for Lybalvi in schizophrenia and bipolar 1 disorder

  Rene Kahn

  2/06/21

  1 item of Media coverage

  Press/Media

• FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder

  Rene Kahn

  2/06/21

  1 item of Media coverage

  Press/Media

• Emotional regulation technique may be effective in disrupting compulsive cocaine addiction

  Rita Goldstein

  31/05/21 → 2/06/21

  15 items of Media coverage

  Press/Media

• Cognitive reappraisal may reduce compulsive drug-seeking behavior in cocaine-addicted individuals

  Rita Goldstein

  31/05/21 → 1/06/21

  2 items of Media coverage

  Press/Media

• Alkermes receives FDA nod for Lybalvi

  Rene Kahn

  1/06/21

  1 item of Media coverage

  Press/Media

• FDA okays new drug option for schizophrenia, bipolar I disorder

  Rene Kahn

  1/06/21

  1 item of Media coverage

  Press/Media

• Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder

  Rene Kahn

  1/06/21

  14 items of Media coverage

  Press/Media

• FDA Approves a New Atypical Antipsychotic With Less Adverse Effects

  Rene Kahn

  1/06/21

  1 item of Media coverage

  Press/Media

• FDA Approves Olanzapine and Samidorphan for Schizophrenia, Bipolar I Disorder

  Rene Kahn

  1/06/21

  1 item of Media coverage

  Press/Media

• Health.-An emotional regulation technique can be effective in curbing compulsive cocaine addiction

  Rita Goldstein

  1/06/21

  1 item of Media coverage

  Press/Media

• A Technique for Regulating Emotion May be Effective in Disrupting Compulsive Cocaine Addiction, a Mount Sinai Study Has Found

  Rita Goldstein

  27/05/21 → 31/05/21

  2 items of Media coverage

  Press/Media

• Mount Sinai Health System Celebrates Its 36th Annual Crystal Party With Virtual Tribute to Front-Line Workers

  Kenneth L. Davis & Miriam Merad

  24/05/21

  2 items of Media coverage

  Press/Media

• Neuroimaging in drug addiction: an eye towards intervention development Online only

  Rita Goldstein

  19/05/21

  1 item of Media coverage

  Press/Media

• Commonly used drugs for schizophrenia linked to greater cognitive impairment

  Jeremy Silverman

  17/05/21 → 18/05/21

  3 items of Media coverage

  Press/Media

• Mount Sinai Honors Front-Line Heath Care Workers in a Unique Crystal Virtual Tribute | Mount Sinai Today

  Kenneth L. Davis & Miriam Merad

  18/05/21

  2 items of Media coverage

  Press/Media

• COMMONLY USED DRUGS FOR SCHIZOPHRENIA LINKED TO GREATER COGNITIVE IMPAIRMENT

  Jeremy Silverman

  17/05/21

  1 item of Media coverage

  Press/Media

• Commonly Used Drugs for Schizophrenia Linked to Greater Cognitive Impairment

  Jeremy Silverman

  17/05/21

  1 item of Media coverage

  Press/Media

• ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2021

  Joseph Buxbaum

  7/05/21

  13 items of Media coverage

  Press/Media

• ORYZON reports results and corporate update for quarter ended March 31, 2021

  Joseph Buxbaum

  7/05/21

  1 item of Media coverage

  Press/Media